Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab for active giant cell arteritis
NL-OMON45005Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sirukumab in giant cell arteritis (GCA) (5 arms), sponsored by GSK. Primary endpoint: Sustained remission at Week 52. Started Jun 2016; status: active, not recruiting.
02
Drugs
sirukumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NL-OMON45005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45005.